Also trades as: 2126.HK (HKSE) · $vol 0M
JWCTF OTC
JW (Cayman) Therapeutics Co. Ltd
1W: +0.0%
1M: +0.0%
3M: -14.8%
YTD: -43.8%
1Y: -58.9%
3Y: -56.6%
$0.20
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$276M
+74.7% ▲
Gross Profit
$119M
+53.8% ▲
Operating Income
-$242M
+47.4% ▲
Net Income
-$541M
+8.4% ▲
EPS (Diluted)
$-1.33
+7.0% ▲
EBITDA
-$162M
+66.9% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $31M | $146M | $174M | $158M | $276M |
| YoY Growth | +0.0% | +373.1% | +19.3% | -9.0% | +74.7% |
| Cost of Revenue | $22M | $87M | $86M | $81M | $157M |
| Gross Profit | $9M | $59M | $88M | $77M | $119M |
| Gross Margin | 29.4% | 40.3% | 50.7% | 48.9% | 43.0% |
| R&D Expenses | $414M | $408M | $414M | $283M | $142M |
| SG&A Expenses | $372M | $371M | $118M | $145M | $219M |
| Operating Expenses | $768M | $915M | $878M | $537M | $361M |
| Operating Income | -$759M | -$856M | -$790M | -$459M | -$242M |
| Operating Margin | -2464.8% | -587.4% | -454.2% | -290.3% | -87.5% |
| Interest Expense | $3M | $7M | $12M | $12M | $11M |
| Income Before Tax | -$702M | -$846M | -$768M | -$591M | -$538M |
| Tax Expense | $0 | $0 | $0 | $0 | $3M |
| Net Income | -$702M | -$846M | -$768M | -$591M | -$541M |
| Net Margin | -2280.5% | -580.7% | -441.7% | -373.3% | -195.8% |
| EPS (Diluted) | $-1.76 | $-2.06 | $-1.87 | $-1.43 | $-1.33 |
| EBITDA | -$739M | -$752M | -$656M | -$489M | -$162M |
| Shares Outstanding | 400M | 410M | 412M | 414M | 416M |